<?xml version="1.0" encoding="UTF-8"?>
<p id="p0030">The pandemic 2019 Coronavirus Disease (COVID-19) caused by Severe Respiratory Syndrome (SARS) coronavirus (CoV) type 2 (SARS-CoV-2) (
 <xref rid="bb0180" ref-type="bibr">WHO, 2020</xref>) prompted the research on therapy and immune-prophylaxis, taking advantage of previous knowledge accumulated on SARS-CoV-1 and animal CoVs (
 <xref rid="bb0030" ref-type="bibr">Decaro et al., 2020</xref>). To date, no specific drug has been approved for the treatment of patients with COVID-19. However, remdesivir, an inhibitor of RNA-dependent RNA polymerase (RdRp), demonstrated promising results (
 <xref rid="bb0065" ref-type="bibr">Kabir et al., 2020</xref>). Moreover, studies to evaluate the efficacy of teicoplanin and monoclonal and polyclonal antibodies against SARS-CoV-2 are currently ongoing (
 <xref rid="bb0065" ref-type="bibr">Kabir et al., 2020</xref>).
</p>
